Author

Panagiota Diamantopoulou Reiter

Observed names: Panagiota Reiter, Reiter P

Institution: Genmab (Denmark)

Observed institutions: Emory University, Genmab (Denmark), Winship Cancer Institute

ORCID: 0009-0006-5597-1252

Observed ORCID: 0009-0006-5597-1252

OpenAlex ID: A5111997832

Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al. · Cancer Research Communications · 6

Safety and Efficacy of HexaBody ‐ DR5 / DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity

2026 · Marije B. Overdijk, Kristin Strumane, et al. · Clinical and Translational Science · 1

Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Data from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S7 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S6 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025 · Kristoffer Staal Rohrberg, Juanita S. Lopez, et al.

Efficacy and Safety of a Fixed Combination of Insulin Degludec/Insulin Aspart in Children and Adolescents with Type 1 Diabetes

2015 · Tadej Battelino, Larry C. Deeb, et al. · 54th Annual ESPE

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

· Rohrberg KS, Lopez JS, et al. · Newcastle University ePrints (Newcastle Univesity)

Works count: 21

Citation count: 7

H-index: 1

I10-index: